Haemonetics Corp (HAE) (Q2 2027) Earnings Call Highlights: Raised Guidance and Expanded
Haemonetics Corp (HAE) reported Q2 2027 earnings, raising guidance but lowering operating margin expansion due to higher costs and investments. CEO Christopher Simon highlighted a multiyear growth opportunity with CSL, though margin contributions are expected in fiscal 2028. The company faces near-term pressures from elevated production and freight costs, with second-half margin expansion weighted toward Q4.
How this was made
The 30-second read
Why it matters
The guidance reduction and cost inflation are likely to weigh on the stock in the near term, though long‑term upside exists if CSL volume ramps.
Market read
Primary corporate news with material guidance change; relevant for traders with exposure to medical‑device equities.
What to watch
Potential upside from high‑20s operating margins once transitory costs subside and from the $300 M PerQseal Elite market opportunity.
Background
Haemonetics provided its Q2 2026 earnings call, highlighting a modest organic growth in interventional technologies, a slowdown in blood‑management growth, and a new capital‑expenditure cycle tied to the CSL contract.
Ticker impact
Q2 earnings call disclosed lowered FY27 operating margin guidance and increased capex, indicating near‑term pressure on margins.
likely pressure as the market prices in the margin guidance reduction and elevated capex spending
Management highlighted a 40‑bp YoY margin decline and a cut to FY27 margin expansion guidance, which typically triggers a sell‑off in the short term.
Market effects
Margin pressure may affect other blood‑management and medical‑device peers as cost inflation spreads.
U.S. healthcare device sector could see modest pullback.
Limited to medical‑device niche; no broad market effect.
Counterpoint
If the CSL partnership ramps faster than expected, margins could rebound in FY28, offering a buying opportunity on the dip.
Key entities
- companyHaemonetics Corp
Medical‑device maker reporting Q2 earnings and revised FY27 guidance.
- partnerCSL
Strategic partner providing a multi‑year device contract.
